Premium
EXPERIENCE WITH TRILOSTANE IN THE TREATMENT OF CUSHING'S SYNDROME
Author(s) -
DEWIS P.,
ANDERSON D. C.,
BU'LOCK DENISE E.,
EARNSHAW ROSEMARY,
KELLY W. F.
Publication year - 1983
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1983.tb00590.x
Subject(s) - endocrinology , medicine
SUMMARY Five patients with pituitary dependent Cushing's syndrome and two with adrenal carcinoma were treated with increasing doses of trilostane (up to 1440 mg daily). There was no consistent fall in serum cortisol levels. In addition there was no rise in the levels of precursors immediately preceding the proposed site of action of trilostane. These results suggest that trilostane does not effectively block the enzyme 3β‐hydroxysteroid dehydrogenase Δ4,Δ5 isomerase in patients with Cushing's syndrome and that it should no longer be recommended for their treatment.